Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2)

Ling, Changquan

doi:10.1016/j.joim.2020.02.004

Cited by 105 publications

(94 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has become a global health emergency, and on March 11, 2020, the World Health Organization (WHO) declared a pandemic status of this novel coronavirus outbreak. Since no approved drug that is specifically targeted to this virus exists at this point in time, drug repositioning/repurposing is thought to be the most effective and feasible approach toward this clear and present threat, and researchers have initiated studies by employing various means in order to find potential therapeutics [2][3][4][5][6][7][8][9][10][11].…”

mentioning

confidence: 99%

Knowledge‐based structural models of SARS‐CoV‐2 proteins and their complexes with potential drugs

et al. 2020

View full text Add to dashboard Cite

Edited by John BriggsThe World Health Organization (WHO) has declared the coronavirus disease 2019 (COVID-19) caused by the novel coronavirus SARS-CoV-2 a pandemic. There is, however, no confirmed anti-COVID-19 therapeutic currently. In order to assist structure-based discovery efforts for repurposing drugs against this disease, we constructed knowledge-based models of SARS-CoV-2 proteins and compared the ligand molecules in the template structures with approved/experimental drugs and components of natural medicines. Our theoretical models suggest several drugs, such as carfilzomib, sinefungin, tecadenoson, and trabodenoson, that could be further investigated for their potential for treating COVID-19.

show abstract

mentioning

confidence: 99%

Knowledge‐based structural models of SARS‐CoV‐2 proteins and their complexes with potential drugs

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Many studies had demonstrated the important role of TCM in inhibiting coronavirus. [20,21,22] Although the patients in this study were mainly mild and moderate, there was still a significant difference in the duration from onset to release form quarantine. The most important basis for release from quarantine is the persistence of negative nucleic acid test results, so the duration from onset to release form quarantine reflects the time it takes the patient to release the virus from the respiratory tract.…”

Section: Discussmentioning

confidence: 82%

Clinical characteristics and reasons of different duration from onset to release from quarantine for patients with COVID-19 Outside Hubei province, China

Tian

Chang

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective: To find out more characteristics and rules of COVID-19 by analyzing the clinical course of COVID-19 patients in a region outside Hubei province. Methods: 37 cases diagnosed adult COVID-19 cases of general characteristics, history of epidemiology, chronic underlying diseases,clinical symptoms and complications, chest CT, biochemical monitoring, severity assessment, treatment and outcome were retrospectively analyzed, and according to the duration from onset to release from quarantine were divided into 20-day group and > 20-day group, compare the similarities and differences between the two groups. Results: Among the 37 patients, 5 were mild, 30 were moderate, 1 was severe and 1 was critical. All the patients were released from quarantine without death. The average duration from onset to release from quarantine was 20.2±6.6 days, The average length of stay from onset to hospitalization was 4.1±3.7 days, and hospitalization duration average 16.1± 6.2 days. The average age was 44.3±1.67 years. 78.4% of cases were caused by exposure to a confirmed patient or the workplace of a confirmed patient. The main symptoms were cough (67.6%), fever( 62.2%), shortness of breath (32.4%), fatigue (24.3%), sore throat (21.6%,) vomiting or diarrhea (21.6%). The white blood cell count was decreased in 27.0% of the patients, and the lymphocyte count was decreased in 62.2% of the patients, of which 43.5% patients were <0.6 × 109/L. On admission, 86.5% of patients with chest CT showed pneumonia, including some asymptomatic patients. 68.8% of patients showed bilateral infiltration. In the > 20-day group, the average age was 49.9±1.38 years old, and the duration from onset to hospitalization was 5.5±3.9 days. Compared with the ≤20-day group, the age was older and and duration was longer, P < 0.05. All the 7 asymptomatic patients were ≤20-day group. When 37 patients were released from quarantine, the white blood cell count of 16.2% patients was <4.0 × 109/L, and the lymphocyte count of 59.5% patients was <1.1×109/L, and the absolute count of white blood cells and lymphocytes was 5.02 ± 1.34×109/L and 1.03± 0.34×109/L respectively , compared with those on admission, P >0.05. Conclusion: The majority of COVID-19 cases in the study area were mild and moderate, with good clinical outcomes. There were some special characteristics in the clinical process. The reasons of duration from onset to release from quarantine were complex. There was no significant change in the number of granulocytes at the time of release from quarantine compared to the time of admission.

show abstract

“…Prescriptions are mainly used to improve immunity, balance human Qi, blood, Yin and Yang, and recover organ function. According to the study of COVID-19 treatment herbs [41,42], Chinese herbal medicines with a higher probability to directly inhibit SARS-CoV-2 have been selected, including Lianqiao, Gancao, Sangbaipi, Jinyinhua, Sangye, Pipaye, and other herbs, commonly used to treat viral pneumonia. Drugs should be selected and utilized according to the corresponding syndrome types.…”

Section: Prospectmentioning

confidence: 99%

Diagnosis and treatment of novel coronavirus pneumonia based on the theory of traditional Chinese medicine

Wang

et al. 2020

Journal of Integrative Medicine

View full text Add to dashboard Cite

Since the outbreak of novel coronavirus pneumonia (coronavirus disease 2019, in December 2019, it has rapidly spread to 187 countries, causing serious harm to the health of people and a huge social burden. However, currently, drugs specifically approved for clinical use are not available, except for vaccines against COVID-19 that are being evaluated. Traditional Chinese medicine (TCM) is capable of performing syndrome differentiation and treatment according to the clinical manifestations of patients, and has a better ability of epidemic prevention and control.The authors comprehensively analyzed the etiology and pathogenesis of COVID-19 based on the theory of TCM, and discussed its syndrome differentiation, treatment and prevention measures so as to provide strategies and reference for the prevention and treatment with TCM. Please cite this article as: Wang SX, Wang Y, Lu YB, Li JY, Song YJ, Nyamgerelt M, Wang XX. Diagnosis and treatment of novel coronavirus pneumonia based on the theory of traditional Chinese medicine. J Integr Med. 2020; Epub ahead of print.

show abstract

Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2)

Cited by 105 publications

References 8 publications

Knowledge‐based structural models of SARS‐CoV‐2 proteins and their complexes with potential drugs

Knowledge‐based structural models of SARS‐CoV‐2 proteins and their complexes with potential drugs

Clinical characteristics and reasons of different duration from onset to release from quarantine for patients with COVID-19 Outside Hubei province, China

Diagnosis and treatment of novel coronavirus pneumonia based on the theory of traditional Chinese medicine

Contact Info

Product

Resources

About